Neural correlates of episodic memory in adults with Down syndrome and Alzheimer's disease.


Journal

Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643

Informations de publication

Date de publication:
03 09 2022
Historique:
received: 19 10 2021
accepted: 19 08 2022
entrez: 3 9 2022
pubmed: 4 9 2022
medline: 9 9 2022
Statut: epublish

Résumé

Adults with Down syndrome are at an ultra-high risk of developing early-onset Alzheimer's disease. Episodic memory deficits are one of the earliest signs of the disease, but their association with regional brain atrophy in the population with Down syndrome has not been explored. We aimed to investigate the neuroanatomical correlates of episodic memory in adults with Down syndrome and symptomatic Alzheimer's disease. Single-center, cross-sectional study. A total of 139 adults with Down syndrome (85 asymptomatic and 54 with symptomatic Alzheimer's disease) were included in the study (mean age 43.6 ± 10.9 years, 46% female). Episodic memory was assessed using the modified Cued Recall Test. Immediate (trial 1 free immediate recall, trial 3 free immediate recall, total free immediate recall score, and total immediate score) and delayed scores (free delayed recall score and total delayed score) were examined. Cortical thickness from magnetic resonance imaging was determined with surface-based morphometry using the FreeSurfer 6.0 software package. The clusters of reduced cortical thickness were compared between symptomatic and asymptomatic participants to create a cortical atrophy map. Then, the correlation between cortical thickness and the modified Cued Recall Test subscores were separately assessed in symptomatic and asymptomatic subjects, controlling for age, sex, and severity of intellectual disability. Compared with asymptomatic participants, those with symptomatic Alzheimer's disease showed a pattern of cortical atrophy in posterior parieto-temporo-occipital cortices. In symptomatic subjects, trial 1 immediate free recall significantly correlated with cortical atrophy in lateral prefrontal regions. Trial 3 free immediate recall and total free immediate recall were associated with the most widespread cortical atrophy. Total immediate score was related to posterior cortical atrophy, including lateral parietal and temporal cortex, posterior cingulate cortex, precuneus, and medial temporal lobe areas. Delayed memory scores were associated with cortical atrophy in temporoparietal and medial temporal lobe regions. No significant relationships were observed between episodic memory measures and cortical atrophy in asymptomatic subjects. Different episodic memory measures were associated with cortical atrophy in specific brain regions in adults with Down syndrome and Alzheimer's disease. These results overlap with those described in sporadic Alzheimer's disease and further support the similarities between Down syndrome-associated Alzheimer's disease and that in the general population.

Sections du résumé

BACKGROUND
Adults with Down syndrome are at an ultra-high risk of developing early-onset Alzheimer's disease. Episodic memory deficits are one of the earliest signs of the disease, but their association with regional brain atrophy in the population with Down syndrome has not been explored. We aimed to investigate the neuroanatomical correlates of episodic memory in adults with Down syndrome and symptomatic Alzheimer's disease.
METHODS
Single-center, cross-sectional study. A total of 139 adults with Down syndrome (85 asymptomatic and 54 with symptomatic Alzheimer's disease) were included in the study (mean age 43.6 ± 10.9 years, 46% female). Episodic memory was assessed using the modified Cued Recall Test. Immediate (trial 1 free immediate recall, trial 3 free immediate recall, total free immediate recall score, and total immediate score) and delayed scores (free delayed recall score and total delayed score) were examined. Cortical thickness from magnetic resonance imaging was determined with surface-based morphometry using the FreeSurfer 6.0 software package. The clusters of reduced cortical thickness were compared between symptomatic and asymptomatic participants to create a cortical atrophy map. Then, the correlation between cortical thickness and the modified Cued Recall Test subscores were separately assessed in symptomatic and asymptomatic subjects, controlling for age, sex, and severity of intellectual disability.
RESULTS
Compared with asymptomatic participants, those with symptomatic Alzheimer's disease showed a pattern of cortical atrophy in posterior parieto-temporo-occipital cortices. In symptomatic subjects, trial 1 immediate free recall significantly correlated with cortical atrophy in lateral prefrontal regions. Trial 3 free immediate recall and total free immediate recall were associated with the most widespread cortical atrophy. Total immediate score was related to posterior cortical atrophy, including lateral parietal and temporal cortex, posterior cingulate cortex, precuneus, and medial temporal lobe areas. Delayed memory scores were associated with cortical atrophy in temporoparietal and medial temporal lobe regions. No significant relationships were observed between episodic memory measures and cortical atrophy in asymptomatic subjects.
CONCLUSIONS
Different episodic memory measures were associated with cortical atrophy in specific brain regions in adults with Down syndrome and Alzheimer's disease. These results overlap with those described in sporadic Alzheimer's disease and further support the similarities between Down syndrome-associated Alzheimer's disease and that in the general population.

Identifiants

pubmed: 36057615
doi: 10.1186/s13195-022-01064-x
pii: 10.1186/s13195-022-01064-x
pmc: PMC9440567
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

123

Subventions

Organisme : NIA NIH HHS
ID : R21 AG056974
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG061566
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

Nat Rev Neurosci. 2015 Sep;16(9):564-74
pubmed: 26243569
J Cogn Neurosci. 2010 Jun;22(6):1083-94
pubmed: 19583477
Nat Commun. 2017 Oct 31;8(1):1214
pubmed: 29089479
Lancet Neurol. 2018 Oct;17(10):860-869
pubmed: 30172624
Alzheimers Dement (Amst). 2020 Jun 28;12(1):e12047
pubmed: 32613076
Neuropsychologia. 2019 Jun;129:83-92
pubmed: 30930301
J Intellect Disabil Res. 2002 Sep;46(Pt 6):472-83
pubmed: 12354318
Neuropsychologia. 2008;46(7):1813-27
pubmed: 18439631
Alzheimers Dement (Amst). 2021 May 20;13(1):e12105
pubmed: 34027014
Am J Psychiatry. 2002 Jan;159(1):74-81
pubmed: 11772693
Am J Intellect Dev Disabil. 2015 Nov;120(6):481-9
pubmed: 26505869
Neuroimage Clin. 2017 Nov 06;17:263-271
pubmed: 29159043
J Intellect Disabil Res. 2002 Mar;46(Pt 3):198-208
pubmed: 11896805
Neurobiol Aging. 2017 May;53:11-19
pubmed: 28192686
Alzheimers Dement. 2016 May;12(5):538-45
pubmed: 26362596
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
J Cogn Neurosci. 2008 May;20(5):762-78
pubmed: 18201133
Neuropsychol Rev. 2017 Mar;27(1):31-45
pubmed: 28289920
Nat Rev Neurosci. 2002 Mar;3(3):201-15
pubmed: 11994752
Hum Brain Mapp. 2019 Oct 15;40(15):4551-4563
pubmed: 31350817
Am J Psychiatry. 1999 Apr;156(4):564-8
pubmed: 10200735
Neuroimage Clin. 2018 Jan 28;18:160-166
pubmed: 29868444
Lancet. 2020 Jun 27;395(10242):1988-1997
pubmed: 32593336
Nat Rev Neurosci. 2003 Oct;4(10):829-39
pubmed: 14523382
Lancet Neurol. 2021 Nov;20(11):930-942
pubmed: 34687637
Nat Rev Neurosci. 2007 Dec;8(12):976-87
pubmed: 18026167
Brain. 1998 Jul;121 ( Pt 7):1239-48
pubmed: 9679776
Neuroimage. 2011 Jan 15;54(2):1530-9
pubmed: 20832485
J Alzheimers Dis. 2010;22(1):285-94
pubmed: 20847406
Alzheimers Dement (Amst). 2020 Sep 13;12(1):e12096
pubmed: 32995465
Neuroimage. 2006 Dec;33(4):1093-103
pubmed: 17011792
Neuroscientist. 2007 Jun;13(3):280-91
pubmed: 17519370
Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):11050-5
pubmed: 10984517
Int J Geriatr Psychiatry. 2017 Dec;32(12):1257-1263
pubmed: 27699865
J Geriatr Psychiatry Neurol. 2010 Jun;23(2):100-8
pubmed: 20029056
Front Hum Neurosci. 2015 Aug 14;9:454
pubmed: 26321939
J Cogn Neurosci. 2010 Jun;22(6):1112-23
pubmed: 19580387
J Neurodev Disord. 2021 Apr 20;13(1):17
pubmed: 33879062
Neuropsychopharmacology. 2010 Jan;35(1):86-104
pubmed: 19776728
J Cogn Neurosci. 2000 Jan;12(1):1-47
pubmed: 10769304
Brain Cogn. 2021 Mar;148:105680
pubmed: 33418512
Neuroimage. 2004;23 Suppl 1:S69-84
pubmed: 15501102
Lancet Neurol. 2016 May;15(6):622-36
pubmed: 27302127
Cereb Cortex. 2009 Mar;19(3):497-510
pubmed: 18632739
Alzheimers Dement. 2019 Feb;15(2):245-257
pubmed: 30503169
Neuroimage. 1999 Feb;9(2):195-207
pubmed: 9931269
Rev Neurol. 2013 Oct 16;57(8):337-46
pubmed: 24081888
Alzheimers Dement (N Y). 2018 May 22;4:224-233
pubmed: 29955665
Cereb Cortex. 1991 Jan-Feb;1(1):103-16
pubmed: 1822725

Auteurs

Bessy Benejam (B)

Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain.

Mateus Rozalem Aranha (MR)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau-Universitat Autònoma de Barcelona, Barcelona, Spain.

Laura Videla (L)

Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain.
Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau-Universitat Autònoma de Barcelona, Barcelona, Spain.
Center of Biomedical Investigation Network for Neurodegenerative Diseases, Madrid, Spain.

Concepción Padilla (C)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau-Universitat Autònoma de Barcelona, Barcelona, Spain.

Silvia Valldeneu (S)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau-Universitat Autònoma de Barcelona, Barcelona, Spain.

Susana Fernández (S)

Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain.

Miren Altuna (M)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau-Universitat Autònoma de Barcelona, Barcelona, Spain.
Center of Biomedical Investigation Network for Neurodegenerative Diseases, Madrid, Spain.

Maria Carmona-Iragui (M)

Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain.
Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau-Universitat Autònoma de Barcelona, Barcelona, Spain.
Center of Biomedical Investigation Network for Neurodegenerative Diseases, Madrid, Spain.

Isabel Barroeta (I)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau-Universitat Autònoma de Barcelona, Barcelona, Spain.
Center of Biomedical Investigation Network for Neurodegenerative Diseases, Madrid, Spain.

Maria Florencia Iulita (MF)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau-Universitat Autònoma de Barcelona, Barcelona, Spain.
Center of Biomedical Investigation Network for Neurodegenerative Diseases, Madrid, Spain.

Víctor Montal (V)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau-Universitat Autònoma de Barcelona, Barcelona, Spain.
Center of Biomedical Investigation Network for Neurodegenerative Diseases, Madrid, Spain.

Jordi Pegueroles (J)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau-Universitat Autònoma de Barcelona, Barcelona, Spain.
Center of Biomedical Investigation Network for Neurodegenerative Diseases, Madrid, Spain.

Alexandre Bejanin (A)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau-Universitat Autònoma de Barcelona, Barcelona, Spain.
Center of Biomedical Investigation Network for Neurodegenerative Diseases, Madrid, Spain.

Sandra Giménez (S)

Multidisciplinary Sleep Unit, Respiratory Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Sofía González-Ortiz (S)

Parc de Salut, Hospital del Mar, Barcelona, Spain.

Sebastián Videla (S)

Clinical Research Support Unit (HUB-IDIBELL), Clinical Pharmacology Department, Bellvitge University Hospital, l'Hospitalet de Llobregat, Barcelona, Spain.
Pharmacology Unit, Department of Pathology and Experimental Therapeutics, School of Medicine and Health Sciences, IDIBELL, University of Barcelona, l'Hospitalet de Llobregat, Barcelona, Spain.

David Bartrés-Faz (D)

Department of Medicine, Faculty of Medicine and Health Sciences, Institute of neurosciences, University of Barcelona, and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Daniel Alcolea (D)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau-Universitat Autònoma de Barcelona, Barcelona, Spain.
Center of Biomedical Investigation Network for Neurodegenerative Diseases, Madrid, Spain.

Rafael Blesa (R)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau-Universitat Autònoma de Barcelona, Barcelona, Spain.
Center of Biomedical Investigation Network for Neurodegenerative Diseases, Madrid, Spain.

Alberto Lleó (A)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau-Universitat Autònoma de Barcelona, Barcelona, Spain.
Center of Biomedical Investigation Network for Neurodegenerative Diseases, Madrid, Spain.

Juan Fortea (J)

Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain. jfortea@santpau.cat.
Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau-Universitat Autònoma de Barcelona, Barcelona, Spain. jfortea@santpau.cat.
Center of Biomedical Investigation Network for Neurodegenerative Diseases, Madrid, Spain. jfortea@santpau.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH